Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 201335 once daily with peginterferon alfa-2a and ribavirin for treatment-naive genotype 1 chronic hepatitis C
2009-012579-90Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2009
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of faldaprevir in hepatitis C virus infection (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Virological response at week 28. Started Jun 2009; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-012579-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012579-90.